Full-length human chromogranin-A cardioactivity: Myocardial, coronary, and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts

Endocrinology

Volumn 154, Issue 9, 2013, Pages 3353-3365

  Pasqua, Teresa ^a   Corti, Angelo ^c   Gentile, Stefano ^a   Pochini, Lorena ^a   Bianco, Mimma ^c   Metz Boutigue, Marie Hélène ^d   Cerra, Maria Carmela ^a,b   Tota, Bruno ^a,b   Angelone, Tommaso ^a,b  

^a UNIVERSITY OF CALABRIA   (Italy)

^b National Institute for Cardiovascular Research   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d HÔPITAL CIVIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ISOPRENALINE;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DILATATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HEART MUSCLE; HEART PERFORMANCE; HYPERTENSION; INOTROPISM; ISOLATED HEART; LUSITROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; WESTERN BLOTTING;

ADRENERGIC BETA-AGONISTS; ALLOSTASIS; ANIMALS; CARDIOTONIC AGENTS; CHROMOGRANIN A; CORONARY CIRCULATION; CORONARY VESSELS; ENDOTHELIN-1; HEART; HOMEOSTASIS; HYPERTENSION; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; OSMOLAR CONCENTRATION; PROTEOLYSIS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, WISTAR; SECOND MESSENGER SYSTEMS; VASODILATION;

EID: 84883158442     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2210     Document Type: Article

References (65)

1. Winkler H, Fischer-Colbrie R. The chromogranin A and B: the first 25 years and future perspectives. Neuroscience. 1992;49(3):497-528.
2. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci. 2007;65(22):2863-2886.
3. Curnis F, Gasparri AM, Longhi R, et al. Chromogranin A binds to αvβ6-integrin and promotes wound healing in mice. Cell Mol Life Sci. 2012;69(16):2791-2801.
4. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a novel measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med. 1984;311(12):764-770.
5. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348(12):1134-1149.
6. Angelone T, Mazza R, Cerra MC. Chromogranin A: a multifaceted cardiovascular role in health and disease. Curr Med Chem. 2012; 19(24):4042-4050.
7. Dev NB, Gayen JR, O'Connor DT, Mahata SK. Chromogranin A and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology. 2010;151(6): 2760-2768.
8. Takiyyuddin MA, Parmer RJ, Kailasam MT, et al. ChromograninA in human hypertension. Influence of heredity. Hypertension. 1995; 26(1):213-220.
9. Ceconi C, Ferrari R, Bachetti T, et al. Chormogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23(12):967-974.
10. Pieroni M, Corti A, Tota B, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007;28(9):1117-1127.
11. Mahapatra NR, O'Connor DT, Vaingankar SM, et al. Hypertension from targeted ablation of chromograninAcan be rescued by the human ortholog. J Clin Invest. 2005;115(7):1942-1952.
12. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in patients with shortness of breath. Heart. 2009;95(18): 1508-1513.
13. Omland T, Dickestein K, Swersen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med. 2003;114(1):25-30.
14. Estensen ME, Hognestad A, Syversen U, et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J. 2006;152(5):927.e1-6.
15. Jansson AM, Rosjo H, Omland T, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J. 2009;30(1):25-32.
16. Rosjo H, Masson S, Latini R, et al. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. Eur J Heart Fail. 2010;12(6):549-556.
17. Simon JP, Bader MF, Aunis D. Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc Natl Acad Sci USA. 1988;85(5):1712-1716.
18. Feldman SA, Eiden LE. The chromogranin a: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol. 2003;14(1):3-23.
19. Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D. Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem. 1993;217(1):247-257.
20. Miserez B, Annaert W, Dillen L, Aunis D, De Potter W. Chromogranin A processing in sympathetic neurons and release of chromogranin A fragments from sheep spleen. FEBS Lett. 1992;314(2): 122-124.
21. Parmer RJ, Mahata M, Gong Y, et al. Processing of chromogranin A by plasmin a novel mechanism for regulating catecholamine secretion. J Clin Invest. 2000;106(7):907-915.
22. Glattard E, Angelone T, Strub JM, et al. Characterization of natural vasostatin-containing peptides in rat heart. FEBS J. 2006;273(14): 3311-3321.
23. Steiner HJ, Weiler R, Ludescher C, Schmid KW, Winkler H. Chromogranin A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem. 1990;38(6): 845-850.
24. Weiergraber M, Pereverzev A, Vajna R, et al. Immunodetection of α1E voltage-gated C2(2+) channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. J Histochem Cytochem. 2000;48(6):807-819.
25. Koshimizu H, Cawley NX, Kim T, Yergey AL, Loh YP. Serpinin: a novel chromogranin A-derived, secreted peptide up-regulates protease nexin-1 expression and granule biogenesis in endocrine cells. Mol Endocrinol. 2011;25(5):732-744.
26. Tota B, Gentile S, Pasqua T, et al. The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive β-adrenergic-like isotrope. FASEB J. 2012;26(7):2888-2898.
27. Koshimizu H, Cawley NX, Yergey AL, Loh YP. Role of pGlu-seprinin, a novel chromogranin A-derived peptide in inhibition of cell death. J Mol Neurosci. 2011;45(2):294-303.
28. Cerra MC, De Iuri L, Angelone T, Corti A, Tota B. Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res Cardiol. 2006; 101(1):43-52.
29. Cerra MC, Gallo MP, Angelonte T, et al. The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB J. 2008;22(11):3992-4004.
30. Ramella R, Boero O, Alloatti G, Angelone T, Levi R, Gallo MP. Vasostatin 1 activates eNOS in endothelial cells through a proteoglycan-dependent mechanism. J Cell Biochem. 2010;110(1):70-79.
31. Mazza R, Mannarino C, Imbrogno S, et al. Crucial role of cytoskeleton reorganization in the negative inotropic effects of chromogranin a-derived peptides in eel and frog hearts. Regul Pept. 2007; 138(2-3):145-151.
32. Angelone T, QuintieriAM,GoumonY, et al. Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin 1-78 and rat CgA1-64) in the rat heart. Regul Pept. 2010;165(1):78-85.
33. Imbrogno S, Angelone T, Corti A, Adamo C, Helle KB, Tota B. Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen Comp Endocrinol. 2004;139(1):20-28.
34. Tota B, Mazza R, Angelone T, et al. Peptides from the N-terminal domain of chromogranin a (vasostatins) exert negative inotropic effects in the isolated frog heart. Regul Pept. 2004;114(2-3):123-130.
35. Angelone T, Quintieri AM, Brar BK, et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology. 2008;149:4780-4793.
36. Angelone T, Quintieri AM, Pasqua T, et al. Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. Am J Physiol Heart Circ Physiol. 2012;302(2):H431-H442.
37. Imbrogno S, Garofalo F, Cerra MC, Mahata SK, Tota B. The catecholamine release-inhibitory peptide catestatin (chromogranin A344-363) modulates myocardial function in fish. J Exp Biol. 2010;213:3636-3643.
38. Cappello S, Angelone T, Tota B, et al. Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol. 2007;293(1):19-27.
39. Penna C, Tullio F, Perrelli MG, Mancardi D, Pagliaro P. Cardioprotection against ischemia/reperfusion injury and chromogranin A-derived peptides. Curr Med Chem. 2012;19(24):4074-4085.
40. Brar BK, Helgeland E, Mahata SK, et al. Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. Regul Pept. 2010;165(1):63-70.
41. Tota B, Angelone T, Mazza R, Cerra MC. The Chromogranin Aderived vasostatins: new players in the endocrine heart. Curr Med Chem. 2008;15(14):1444-1451.
42. Veschini L, Crippa L, Dondossola E, Doglioni C, Corti A, Ferrero E. The vasostatin-1 fragment of chromogranin a preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB J. 2011;25(11):3906-3914.
43. Corti A, Gasparri A, Chen FX, et al. Characterisation of circulating chromograninAin human cancer patients. Br J Cancer. 1996;73(8): 924-932.
44. Ratti S, Curnis F, Longhi R, et al. Structure-activity relationship of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem. 2000;275(38): 29257-29263.
45. Hassanabad ZF, Furman BL, Parratt JR, Aughey E. Coronary endothelial dysfunction increases the severity of ischemia-induced ventricular arrhythmias in rat isolated perfused heart. Basic Res Cardiol. 1998;93(4):241-249.
46. Gayen JR, Zhang K, Ramachandra Rao SP, et al. Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin A (Chga) gene. Circ Cardiovasc Genet. 2010; 3(5):414-425.
47. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 1998;39(1):89-105.
48. Schulz E, Gori T, Munez T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34(6):665-673.
49. Fournier I, Gaucher D, Chich JF, et al. Processing of chromogranins/secretogranin in patients with diabetic retinopathy. Regul Pept. 2011;167(1):118-124.
50. Thiele C, Huttner WB. The disulfide-bonded loop of chromogranins, which is essential for sorting to secretory granules, mediates homodimerization. J Biol Chem. 1998;273(2):1223-1231.
51. Yoo SH, Lewis MS. Dimerization and tetramerization properties of the C-terminal region of chromogranin A: a thermodynamic analysis. Biochemistry. 1993;32(34):8816-8822.
52. Celik I, Surucu O, Dietz C, et al. Therapeutic efficacy of the endostatin exhibits a biphasic dose-response curve. Cancer Res. 2005; 65(23):11044-11050.
53. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-α- mediated down-regulation of angiogenesis-related genes therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5(10):2726-2734.
54. Vaingankar SM, Li Y, Biswas N, et al. Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertension. 2010;28(4):817-825.
55. 2+ on heterodimer and heterotetramer formation by chromogranin A and chromogranin B. J Biol Chem. 1996;271(29):17041-17046.
56. Anand-Srivastava MB. Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Relationship to adenylate cyclase inhibition. Biochem J. 1992; 288(Pt 1):79-85.
57. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev. 2009;89(2):481-534.
58. Abi-Gerges N, Fischmeister R, Mery PF. G protein-mediated inhibitory effect of nitric oxide on L-type Ca2+current in rat ventricular myocytes. J Physiol. 2001;531(Pt 1):117-130.
59. Stojanovic MO, Ziolo MT, Wahler GM, Wolska BM. Anti-adrenergic effects of nitric oxide donor SIN-1 in rat cardiac myocytes. Am J Physiol Cell Physiol. 2001;281(1):C342-C349.
60. Crabos M, Coste P, Paccalin M, et al. Reduced basal NO-mediated dilation and decreased endothelial NO-synthase expression in coronary vessels of spontaneously hypertensive rats. J Mol Cell Cardiol. 1997;29(1):55-65.
61. Kojda G, Kottenberg K, Hacker A, Noack E. Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats. Pharm Acta Helv. 1998; 73(1):27-35.
62. Gupta PK, Ramanan B, Mactaggart JN, et al. Risk index for predicting perioperative stroke, myocardial infarction, or death risk in asymptomatic patients undergoing carotid endarterectomy. J Vasc Surg. 2013;57(2):318-326.
63. Krylova MI. Chromogranin A: immunocytochemical localization in secretory granules of frog atrial cardiomyocytes. Tsitologiia. 2007; 49(7):538-543.
64. Biswas N, Curello E, O'Connor DT, Mahata SK. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin [Chga(364-384)]. Cell Tissue Res. 2010;342(3):353-361.
65. Müller AL, Dhalla NS. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev. 2012;17(3): 395-409.